Merus N.V. (MRUS)
After hours:
- Globe Newswire
Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
- Robust 34% overall response rate and 9.1 months median duration of response across multiple NRG1+ tumor types - Zenocutuzumab observed to be well-tolerated - Oral presentation with additional patient data at ASCO on June 5, 2022, 9:45 -11:15 a.m. CT - Investor call to discuss clinical results on Sunday, June 5 at 6:00 p.m. CT UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncol
- Zacks
Down 32.1% in 4 Weeks, Here's Why Merus N.V. (MRUS) Looks Ripe for a Turnaround
Merus N.V. (MRUS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Zacks
Merus N.V. (MRUS) Loses 30.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Merus N.V. (MRUS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
